CHE

Business Context and Reporting Period

Company: Chemed Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 1995
Business Overview: Chemed operates through four primary segments: National Sanitary Supply (sanitary products), Roto-Rooter (plumbing and drain cleaning), Veratex (medical and dental supplies), and Patient Care (home health services).

Key Financial Metrics

Note: Q2 Net Income for 1994 included $3.591 million from discontinued operations, whereas Q2 1995 had none.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 10% in Q2 and 11% for the six-month period compared to 1994.
  • National Sanitary Supply: Sales up 11% (Q2) and 12% (6 months) due to volume increases and price hikes.
  • Patient Care: Sales surged 29% (Q2) and 32% (6 months) driven by new branch openings.
  • Roto-Rooter: Sales up 3% (Q2) and 4% (6 months); growth in core services offset by a 10% decline in the ServiceAmerica contract business following a divestiture.
  • Veratex: Sales up 4% (Q2 and 6 months), but operating margins declined due to retail price competition.
• Profitability: Income from continuing operations increased 20% in Q2 and 39% for the six-month period. However, reported Net Income decreased in both periods due to the absence of significant gains from discontinued operations (Omnicare) recorded in 1994.
• Liquidity: Cash and cash equivalents dropped significantly from $4.722 million (Dec 31, 1994) to $0.215 million (June 30, 1995). This was driven by operating cash outflows, capital expenditures, and an $8.553 million acquisition of the CSD Medical Division.
• Investments: "Other income" increased significantly due to gains on the sale of marketable securities ($1.858 million after-tax in Q2 1995).

Guidance, Outlook, and Management Commentary

• Divestitures: In July 1995 (post-period), the Veratex Retail division was sold to Henry Schein Inc. for $10 million cash plus a $4.1 million note. This allows Veratex to focus on its wholesale manufacturing (Tidi Products). The sale is not expected to materially impact annual results.
• Acquisitions: The Veratex Group acquired the CSD Medical Division for $6.9 million cash plus contingent payments. Results are considered immaterial to consolidated results.
• Liquidity Outlook: Management states that with approximately $38.125 million in unused lines of credit, sources of capital and liquidity are satisfactory for foreseeable needs.
• Tax Rate: The effective income tax rate for Q2 1995 was 38.5%, higher than the 37.4% in Q2 1994, primarily due to higher state and local tax rates.
• Risks/Contingencies: The filing notes contingent payments of up to $750,000 related to the CSD acquisition and up to $2 million related to the Veratex Retail sale, dependent on future sales performance.

Investor Verification Checklist

• Cash Position: Verify the sustainability of operations given the cash balance dropped to $215,000, relying heavily on $38 million in credit lines.
• Discontinued Operations Impact: Confirm that the decline in Net Income (vs. 1994) is fully explained by the one-time gains from Omnicare in the prior year, rather than operational deterioration.
• Veratex Margin Pressure: Monitor the impact of the retail divestiture on Veratex's future margins, as the segment's margin declined from 7.1% to 5.6% in Q2 1995.
• Debt Levels: Review the total debt load ($96.2 million total debt including current portion) relative to the reduced cash reserves.
• Contingent Liabilities: Track the potential additional payments of up to $2.75 million related to recent M&A activity.